First-Line Lorlatinib vs Crizotinib in ALK-Positive Advanced NSCLC
This was a planned interim analysis of a phase 3 study comparing lorlatinib and crizotinib as a frontline treatment for patients with ALK-positive NSCLC.
Home
Osimertinib Found to Reduce Risk of CNS Recurrence in Resected EGFRm NSCLC
Analysis suggests osimertinib lowers the risk of CNS recurrence in patients with completely resected EGFR-mutated NSCLC.
The COVID-19 Pandemic Is Affecting the Well-Being of Oncologists
Many oncologists across the world are experiencing decreased feelings of well-being and increased burnout as a result of the COVID-19 pandemic.
Timing and Type of Prior Cancer Therapy May Influence Mortality in Patients With Cancer Diagnosed With COVID-19
“Immunotherapy-alone [patients] had similar rates of death compared with those not on treatment within the past year,” Dr Wise-Draper emphasized.
COVID-19 Pandemic Resulted in Cancer Treatment Modification, Increased Stress
Anticancer treatment modifications resulted in posttraumatic stress among patients and their health care providers.
Palbociclib Plus Letrozole Deemed Effective in Advanced Endometrial Cancer
Palbociclib plus letrozole prolonged PFS and maintained QoL compared with placebo plus letrozole, according to results from a phase 2 trial.
Off-Label Use of Targeted Therapy Shows Benefit in Some Patients With Advanced Cancers
Aims of the DRUP trial were to facilitate access to off-label targeted therapy for patients with advanced cancers and to collect data on the safety and efficacy of this approach.
Recall of Specific Types of Breast Implants and Tissue Expanders Has Far-Reaching Impact on Patients With Breast Cancer
In Japan, insurance coverage for breast implantation is limited to procedures using Allergen-manufactured products.
Capmatinib Shows Clinical Activity in MET Exon 14–Mutated NSCLC
Capmatinib showed clinical activity in patients with MET exon 14–mutated advanced non–small cell lung cancer, reported a phase 2 trial.
Study Documents Real-World Survival Improvement for Non-Small Cell Lung Cancer
An analysis finds that mortality rates for NSCLC are falling faster than incidence rates, which the authors attributed to the introduction of targeted therapies in 2013.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Lung Cancer
